$AVTX

Avalo Therapeutics, Inc.

Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody being evaluated in a Phase 2 trial for hidradenitis suppurativa. Avalo sponsors the LOTUS trial and is responsible for developing and commercializing abdakibart. The company also has legacy candidates, including quisovalimab, AVTX-006, AVTX-008 and AVTX-913, which it is not currently developing clinically and for which it is exploring strategic alternatives. Avalo holds licensed rights to abdakibart and may earn money through commercialization if the candidate is approved, as well as by out-licensing compounds, indications or geographic rights. It may also acquire or in-license drug candidates. Avalo is headquartered in Wayne, Pennsylvania.

AlphAI earnings readThird Quarter 2026 · NOV 5Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business UpdatesVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $AVTX in the last 7 days.

No SEC Form 4 filings for $AVTX in the last 30 days.

See all $AVTX insider activity →

Stifel cuts Avalo Therapeutics stock price target on trial data

Stifel reduced its price target for Avalo Therapeutics (AVTX) to $30 from $39, citing trial data showing AVTX-009 achieved a 17% HISCR75 delta. The company plans FDA feedback by year-end 2026 and a Phase 3 trial in early 2027. Other analysts have also updated their ratings and targets for AVTX.

Avalo Therapeutics, Inc. (AVTX): Entry into a Material Definitive Agreement

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Jefferies Sales Agreement”), with Jefferies LLC (“Jefferies”) with respect to an “at-the-market” offering progra

AVTX sentiment & insider activity

Recent AVTX coverage spans financial news, earnings and technology.

What's driving AVTX

  • Wedbush kept Avalo Therapeutics at Outperform but cut its price target to $20 from $22, citing a 9.1% decrease. The new target suggests a 201.7% upside from the Nov 5 close of $6.63. Recent analyst price targets for Avalo range from $10 to $22.

    tradingview.com · Nov 6, 2026

  • Analyst target cuts and modest trial efficacy suggest the stock will face downside pressure.

    investing.com · Nov 6, 2026

  • The new ATMS program provides up to $200 M of financing, potentially diluting existing shareholders but giving the company cash for development.

    SEC EDGAR 8-K · Nov 5, 2026

  • The narrower loss and strong cash position may reduce downside pressure and support modest upside.

    tradingview.com · Nov 5, 2026

  • The report shows a solid cash runway and progress toward Phase 3, which may support the stock.

    SEC EDGAR 8-K · Nov 5, 2026

AlphAI scores every news story that mentions AVTX with an AI model for sentiment and relevance, and aggregates insider trades from Avalo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVTX

Score
$AVTXHighOffering· $200M · proposed

Avalo Therapeutics, Inc. (AVTX): Entry into a Material Definitive Agreement

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Jefferies Sales Agreement”), with Jefferies LLC (“Jefferies”) with respect to an “at-the-market” offering progra

$AVTXMedEarnings

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates • Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 • Advancing AVTX-010, a next-gen

Oppenheimer cuts Avalo Therapeutics price target on trial concerns

Oppenheimer reduced its price target for Avalo Therapeutics (NASDAQ:AVTX) to $16 from $35, citing concerns over trial results for a competing drug. The stock has fallen 40% in a week, trading at $6.61. Despite this, Oppenheimer maintains an Outperform rating, noting the company's strong cash position and potential undervaluation. Other analysts have mixed views, with some downgrading and others maintaining Buy ratings.

H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy

H.C. Wainwright reiterated a Buy rating and $30.00 price target for Avalo Therapeutics (NASDAQ:AVTX), which is trading near its 52-week low. The firm expects positive Phase 3 results from AbbVie's INTREPID study by mid-November or December 2026. Avalo has a strong balance sheet and upcoming FDA milestones in 2026-2027. Cantor Fitzgerald also reiterated an Overweight rating, citing IL-1 inhibition's potential. Three analysts recently raised earnings estimates.

Related tickers